All In Biotech

Drug Trial Radar · NCT07596680

CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases

Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CD19/BCMA-Targeted CAR-T Cell Injection in Patients With Autoantibody-Mediated Autoimmune Diseases

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Apr 30, 2028

Study completion Apr 30, 2029

Sponsor

Sponsor type
Industry
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with autoantibody-mediated autoimmune diseases. The enrolled population consists of patients with active autoimmune diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), ANCA-associated vasculitis (AAV), idiopathic inflammatory myopathies (IIM), Sjögren's syndrome (SS), among others. The CAR-T cell dose used in this study is 6×10⁶ CAR⁺ T cells/kg. Six subjects will be enrolled for each indication, with a total of 30 subjects to be enrolled.

Conditions

  • SLE - Systemic Lupus Erythematosus
  • Systemic Sclerosis
  • ANCA Associated Vasculitis
  • Idiopathic Inflammatory Myopathies
  • Sjögren Syndrome

Interventions

  • RD06-05 CAR-T Cell InjectionDrug

    CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SLE (systemic lupus erythematosus)Time frame: 2 years
  2. SLE (systemic lupus erythematosus)Time frame: 2 years
  3. SLE (systemic lupus erythematosus)Time frame: 2 years
  4. SLE (systemic lupus erythematosus)Time frame: 2 years
  5. SLE (systemic lupus erythematosus)Time frame: 2 years
  6. SLE (systemic lupus erythematosus)Time frame: 2 years
  7. AAV (ANCA-associated vasculitis)Time frame: 2 years
  8. AAV (ANCA-associated vasculitis)Time frame: 2 years
  9. IIM (idiopathic inflammatory myopathies)Time frame: 2 years
  10. SSc (systemic sclerosis)Time frame: 2 years
  11. SSc (systemic sclerosis)Time frame: 2 years
  12. SSc (systemic sclerosis)Time frame: 2 years
  13. SS (Sjögren's syndrome )Time frame: 2 years
  14. SS (Sjögren's syndrome )Time frame: 2 years
  15. SS (Sjögren's syndrome )Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.